Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Provincial Medical Genetics Program of British Columbia, |
RCV002071030 | SCV002320850 | likely pathogenic | Neurofibromatosis, type 2 | 2022-01-01 | criteria provided, single submitter | clinical testing | |
Genetics and Molecular Pathology, |
RCV002071030 | SCV002556808 | pathogenic | Neurofibromatosis, type 2 | 2021-08-19 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004044907 | SCV005034264 | pathogenic | Hereditary cancer-predisposing syndrome | 2023-10-11 | criteria provided, single submitter | clinical testing | The p.L398P pathogenic mutation (also known as c.1193T>C), located in coding exon 12 of the NF2 gene, results from a T to C substitution at nucleotide position 1193. The leucine at codon 398 is replaced by proline, an amino acid with similar properties. This mutation was detected in multiple unrelated individuals with clinical features of NF2-related schwannomatosis and co-segregated with disease in a large family (Heineman TE et al. Otol Neurotol, 2015 Jun;36:908-14; external communications). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. |